Healthcare provider profile · identity verified

Michael D Jones, MD

Allopathic & Osteopathic Physicians|Family Medicine · MCDONOUGH, GA · NPI 1578537734

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael D Jones, MD received $19.85 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$19.85

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$19.85	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$19.85	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Lilly USA, LLC	$19.85	1	2025
Source payment records 2025-12-21 · Lilly USA, LLC · $19.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	143	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	143	40
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	107	28
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	101	24

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	635	195
Amlodipine Besylate	Amlodipine Besylate	630	202
Rosuvastatin Calcium	Rosuvastatin Calcium	448	147
Levothyroxine Sodium	Levothyroxine Sodium	345	102
Lisinopril	Lisinopril	269	82
Metformin Hcl	Metformin Hcl	257	69
Omeprazole	Omeprazole	248	81
Losartan Potassium	Losartan Potassium	241	81
Metoprolol Succinate	Metoprolol Succinate	224	66
Gabapentin	Gabapentin	205	73
Metformin Hcl Er	Metformin Hcl	187	55
Tizanidine Hcl	Tizanidine Hcl	179	72
Famotidine	Famotidine	162	62
Pantoprazole Sodium	Pantoprazole Sodium	160	53
Hydrochlorothiazide	Hydrochlorothiazide	148	46
Simvastatin	Simvastatin	148	43
Jardiance	Empagliflozin	143	40
Potassium Chloride	Potassium Chloride	140	45
Farxiga	Dapagliflozin Propanediol	138	34
Furosemide	Furosemide	132	53
Allopurinol	Allopurinol	131	39
Fluticasone Propionate	Fluticasone Propionate	124	53
Albuterol Sulfate Hfa	Albuterol Sulfate	120	54
Tamsulosin Hcl	Tamsulosin Hcl	118	32
Zolpidem Tartrate	Zolpidem Tartrate	112	29
Alprazolam	Alprazolam	110	18
Mounjaro	Tirzepatide	107	28
Trazodone Hcl	Trazodone Hcl	107	31
Pioglitazone Hcl	Pioglitazone Hcl	104	35
Carvedilol	Carvedilol	103	33
Trulicity	Dulaglutide	101	24
Metoprolol Tartrate	Metoprolol Tartrate	95	34
Meloxicam	Meloxicam	93	38
Sertraline Hcl	Sertraline Hcl	92	29
Pravastatin Sodium	Pravastatin Sodium	88	33
Glimepiride	Glimepiride	86	22
Olmesartan Medoxomil	Olmesartan Medoxomil	84	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	82	25
Tramadol Hcl	Tramadol Hcl	82	22
Atenolol	Atenolol	81	25
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	80	23
Montelukast Sodium	Montelukast Sodium	76	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	75	24
Glipizide	Glipizide	66	20
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	64	56
Escitalopram Oxalate	Escitalopram Oxalate	62	19
Glipizide Er	Glipizide	61	17
Diclofenac Sodium	Diclofenac Sodium	60	25
Hydralazine Hcl	Hydralazine Hcl	60	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	19
Ezetimibe	Ezetimibe	55	18
Januvia	Sitagliptin Phosphate	52	15
Lovastatin	Lovastatin	51	14
Ibandronate Sodium	Ibandronate Sodium	48	15
Synthroid	Levothyroxine Sodium	48	11
Linzess	Linaclotide	45	13
Clopidogrel	Clopidogrel Bisulfate	44	16
Spironolactone	Spironolactone	44	14
Duloxetine Hcl	Duloxetine Hcl	43	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	17
Pregabalin	Pregabalin	42	14
Finasteride	Finasteride	41	12
Valacyclovir	Valacyclovir Hcl	41	15
Valsartan	Valsartan	39	11
Topiramate	Topiramate	38	12
Bupropion Hcl Sr	Bupropion Hcl	37	13
Bupropion Xl	Bupropion Hcl	37	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	37	30
Fenofibrate	Fenofibrate	36	11
Vitamin D2	Ergocalciferol (Vitamin D2)	36	12
Donepezil Hcl	Donepezil Hcl	35	13
Estradiol	Estradiol	35	suppressed
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	34	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	34	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	33	suppressed
Nifedipine Er	Nifedipine	32	12
Alendronate Sodium	Alendronate Sodium	31	11
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Baclofen	Baclofen	30	15
Buspirone Hcl	Buspirone Hcl	30	14
Chlorthalidone	Chlorthalidone	30	13
Nortriptyline Hcl	Nortriptyline Hcl	28	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	27	27
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Clonidine Hcl	Clonidine Hcl	27	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Fluconazole	Fluconazole	26	20
Meclizine Hcl	Meclizine Hcl	26	12
Ozempic	Semaglutide	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Azithromycin	Azithromycin	25	25
Methylprednisolone	Methylprednisolone	25	25
Clonazepam	Clonazepam	24	suppressed
Niacin Er	Niacin	24	suppressed
Raloxifene Hcl	Raloxifene Hcl	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Myrbetriq	Mirabegron	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	20	suppressed
Eliquis	Apixaban	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Colesevelam Hcl	Colesevelam Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	11
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Prednisone	Prednisone	15	14
Sucralfate	Sucralfate	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Cephalexin	Cephalexin	14	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Ramipril	Ramipril	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	13	suppressed
Colchicine	Colchicine	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Dutasteride-Tamsulosin	Dutasteride/Tamsulosin Hcl	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Lorazepam	Lorazepam	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$19.85 · 1 records	Lilly USA, LLC	JARDIANCE	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error